For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Tesamorelin

Also known as: Egrifta

Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.

Real-time market data

Pricing for Tesamorelin

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$8.11/mg

range $3.40–$28.50/mg

Sellers

85

from $0.00

45-day trend

-21.9%

vs 45-day avg $/mg

79 of 85 sellers have a current price· 45 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Tesamorelin

257 third-party tests across 34 vendors. Each card links to the full report.

All 257 COAs for Tesamorelin →
Measured purity 98.0%–100.0% across 145 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.60 %
Jul 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM-13

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Optima Supply· batch OS-2026-1763

Aggregated · 3rd-party listing
98.51 %
Jul 2026
Janoshik Analytical Limited

For

Tesamorelin

by Hydro Research Peptides· batch HR-2026-4509

Aggregated · 3rd-party listing
99.97 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch tsm20-04

Aggregated · 3rd-party listing
99.91 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Profound Aminos· batch Black Cap

✓ Vendor-published
99.83 %
Jun 2026
TrustPointe Analytics Moderate

For

Tesamorelin

by Peptide Partners· batch TES202607

COA on file
Aggregated · 3rd-party listing
99.89 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10-06022026

Aggregated · 3rd-party listing
99.81 %
Jun 2026
Freedom Diagnostics Moderate

For

Tesamorelin

by Peptide Plugs· batch 136-02-SM-WT

Aggregated · 3rd-party listing
99.37 %
Jun 2026
Horizon Analytical

For

Tesamorelin

by Blank Peptides· batch B-3699671-P

Aggregated · 3rd-party listing
99.78 %
Jun 2026
ILS Labs Strong

For

Tesamorelin

by Voltera Sciences· batch TSM10.05.28.26

Aggregated · 3rd-party listing
99.26 %
Jun 2026
Janoshik Analytical Limited

For

Tesamorelin

by Verified Peptides· batch TM07261020J

✓ Vendor-published
99.71 %
May 2026
TrustPointe Analytics Moderate

For

Tesamorelin

by Peptide Partners· batch SPL-3947

COA on file
Aggregated · 3rd-party listing
99.00 %
May 2026
Ethos Analytics Strong · HPLC

For

Tesamorelin

by OROS Research· batch OR-LPTES5-526-B6

Aggregated · 3rd-party listing
99.77 %
May 2026
ILS Labs Strong · HPLC

For

Tesamorelin

by Glacier Aminos· batch TES10GA-07

Aggregated · 3rd-party listing
99.47 %
May 2026
ILS Labs Strong · HPLC

For

Tesamorelin

by Crush Research· batch CR-TSM20-0307-1

Aggregated · 3rd-party listing
99.24 %
May 2026
Janoshik Analytical Limited · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-10-002

Aggregated · 3rd-party listing
99.23 %
May 2026
Janoshik Analytical Limited · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-20-004

✓ Vendor-published
99.02 %
May 2026
Vanguard Laboratory Strong

For

Tesamorelin/Ipamorelin

by Licensed Peptides· batch Green Cap

COA on file
Aggregated · 3rd-party listing
99.48 %
May 2026
ILS Labs Strong

For

Tesamorelin

by NG Peptide· batch TSM20-3

✓ Vendor-published
99.43 %
May 2026
FreedomDiagnosticsTesting.com

For

Tesamorelin

by Forge Performance Co.· batch Clear Blue Cap

COA on file
Aggregated · 3rd-party listing
99.78 %
May 2026
ILS Labs Strong

For

Tesamorelin

by Ion Peptide· batch TSM10-05042026

✓ Vendor-published
99.78 %
May 2026
ILS Laboratories

For

Tesamorelin

by Ion Peptide· batch TSMH10-0504206

COA on file
✓ Vendor-published
99.74 %
May 2026
ILS Laboratories

For

Tesamorelin - 10mg

by Ion Peptide· batch TSH10-0504226

COA on file
✓ Vendor-published
99.94 %
May 2026
Kovera Labs

For

Tesamorelin

by Reta One Labs· batch TS100526

COA on file
Research depth

23 citations indexed for Tesamorelin

All research on Tesamorelin →

case-report · 2026

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists

Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).

animal · 2026

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model

The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.

meta-analysis · 2026

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

Study · 2026

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants

Study · 2026

The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment

Cognitive decline with age and other clinical conditions are linked with reduced hypothalamic-pituitary-adrenal (HPA) axis function.